Multicancer Detection Tests: Navigating Promise, Pitfalls, and the Path Forward for Primary Care

PURPOSE: Blood-based multicancer detection (MCD) tests are rapidly emerging in clinical practice, offering the potential to detect cancers-including those without established screening modalities-through a single assay. Their expanding commercial availability and growing patient awareness have propelled early clinical adoption despite limited evidence on effectiveness. METHODS: This special report synthesizes the current landscape of MCD testing and examines the implications for primary care physicians (PCPs), who are often the first clinicians patients approach about these new technologies. RESULTS: Evidence supporting MCD testing remains immature. A recent systematic review indicates insufficient data regarding mortality benefit, cancer detection outcomes, or quality- of-life impact. Despite this, MCD use is increasing through industry partnerships and health-system-driven implementation programs. Early adopters-including large health systems and cancer centers-have developed navigation pathways, diagnostic follow-up resources, and registries to support real-world evidence generation. Qualitative research with PCPs and physician leaders reveals recurrent concerns: patient-driven demand, insufficient practice guidelines, unclear diagnostic pathways, cost and equity challenges, and malpractice risk. Historical experience with prostate specific antigen (PSA) screening underscores the potential for a de facto standard of care to emerge ahead of robust evidence. CONCLUSION: Primary care physicians face significant informational, procedural, and medicolegal uncertainty as MCD tests proliferate. Responsible integration will require coordinated evidence generation, including contributions from primary care practices. Until stronger evidence emerges, shared decision making (SDM) remains essential for navigating the promise and pitfalls of MCD testing in routine practice. PRIMARY: care physicians are confronting MCD testing issues ahead of evidence, requiring preparedness for patient-driven inquiries, clear SDM practices, and participation in evidence-generation.